Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study.
Federmann B, Bornhauser M, Meisner C, Kordelas L, Beelen DW, Stuhler G, Stelljes M, Schwerdtfeger R, Christopeit M, Behre G, Faul C, Vogel W, Schumm M, Handgretinger R, Kanz L, Bethge WA. Federmann B, et al. Among authors: meisner c. Haematologica. 2012 Oct;97(10):1523-31. doi: 10.3324/haematol.2011.059378. Epub 2012 Apr 4. Haematologica. 2012. PMID: 22491731 Free PMC article. Clinical Trial.
German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma.
Herrlinger U, Schabet M, Brugger W, Kortmann RD, Küker W, Deckert M, Engel C, Schmeck-Lindenau HJ, Mergenthaler HG, Krauseneck P, Benöhr C, Meisner C, Wiestler OD, Dichgans J, Kanz L, Bamberg M, Weller M. Herrlinger U, et al. Among authors: meisner c. Ann Neurol. 2002 Feb;51(2):247-52. doi: 10.1002/ana.10102. Ann Neurol. 2002. PMID: 11835382 Clinical Trial.
Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study.
Bethge WA, Lange T, Meisner C, von Harsdorf S, Bornhaeuser M, Federmann B, Stadler M, Uharek L, Stelljes M, Knop S, Wulf G, Trenschel R, Vucinic V, Dittmann H, Faul C, Vogel W, Kanz L, Bunjes D. Bethge WA, et al. Among authors: meisner c. Blood. 2010 Sep 9;116(10):1795-802. doi: 10.1182/blood-2010-02-270538. Epub 2010 Jun 7. Blood. 2010. PMID: 20530284 Free article. Clinical Trial.
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis.
Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B, Peest D, Kaufmann M, Bunjes D, Straka C, Fischer T, Sezer O, Hentrich M, Ostermann H, Bassermann F, Hess G, Hertenstein B, Freund M, Kropff M, Schmidt CA, Wolf HH, Jung W, Frickhofen N, Mielke S, Bargou RC, Maschmeyer G, Svaldi M, Langer CH, Gramatzki M, Hebart H, Kanz L, Einsele H; Deutsche Studiengruppe Multiples Myelom. Knop S, et al. Among authors: meisner c. Leukemia. 2019 Nov;33(11):2710-2719. doi: 10.1038/s41375-019-0537-2. Epub 2019 Aug 28. Leukemia. 2019. PMID: 31462732 Clinical Trial.
A CTL epitope from human cytomegalovirus IE1 defined by combining prediction of HLA binding and proteasomal processing is the target of dominant immune responses in patients after allogeneic stem cell transplantation.
Hebart H, Rauser G, Stevanovic S, Haenle C, Nussbaum AK, Meisner C, Bissinger AL, Tenzer S, Jahn G, Loeffler J, Rammensee HG, Schild H, Einsele H. Hebart H, et al. Among authors: meisner c. Exp Hematol. 2003 Oct;31(10):966-73. doi: 10.1016/s0301-472x(03)00203-0. Exp Hematol. 2003. PMID: 14550813 Free article.
189 results